Hui Gan
YOU?
Author Swipe
View article: IMMU-35. CD3⁺CD4⁻CD8⁻ (Double-Negative) T-cells Provide Inflammatory Signals That Influence Myeloid Cells and Enhance Survival in Glioblastoma
IMMU-35. CD3⁺CD4⁻CD8⁻ (Double-Negative) T-cells Provide Inflammatory Signals That Influence Myeloid Cells and Enhance Survival in Glioblastoma Open
Despite responses in other malignancies, immune checkpoint inhibitor immunotherapy does not significantly improve outcomes for most glioblastoma (GBM) patients. Our group previously showed that anti-PD-1 therapy extended survival in CD8-kn…
View article: DDDR-19. An optimized explant organoid method for preclinical brain tumour research
DDDR-19. An optimized explant organoid method for preclinical brain tumour research Open
Tumour heterogeneity presents a significant obstacle to identifying effective treatments for brain cancer, explaining the ineffectiveness of standard treatments. Patient-derived brain tumour explant organoids (GBOs) replicate this heteroge…
View article: CTNI-25. MULTI-SITE, PROSPECTIVE TRIAL EVALUATING FET-PET IN GLIOBLASTOMA (FIG) STUDY (TROG 18.06): CENTRAL NUCLEAR MEDICINE AND RADIATION ONCOLOGY REVIEW OF FET-PET BIOLOGIC TARGET VOLUME DELINEATION FOR RADIATION PLANNING
CTNI-25. MULTI-SITE, PROSPECTIVE TRIAL EVALUATING FET-PET IN GLIOBLASTOMA (FIG) STUDY (TROG 18.06): CENTRAL NUCLEAR MEDICINE AND RADIATION ONCOLOGY REVIEW OF FET-PET BIOLOGIC TARGET VOLUME DELINEATION FOR RADIATION PLANNING Open
BACKGROUND The prospective multi-site trial evaluating O-(2-[18F]-fluoroethyl)-L-tyrosine Positron Emission Tomography (FET-PET) in Glioblastoma (FIG) study is currently recruiting. This abstract aims to evaluate the impact of full central…
View article: EXTH-46. IL-15 armored glypican-3 chimeric antigen receptor T cells exhibit antitumor in vitro and in murine models of glioblastoma
EXTH-46. IL-15 armored glypican-3 chimeric antigen receptor T cells exhibit antitumor in vitro and in murine models of glioblastoma Open
INTRODUCTION Glioblastoma is the most common primary brain tumor in adults and is lethal in most patients. Recently, chimeric antigen receptor T cell (CAR-T) therapy has emerged as a potential treatment option for patients with multiple ma…
View article: TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma
TIP-10. Update on GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma Open
BACKGROUND GBM AGILE (Glioblastoma Adaptive, Global, Innovative Learning Environment) is a multi-arm, international, seamless Phase 2/3 response adaptive randomization (RAR) platform trial designed to efficiently identify investigational t…
View article: Establishment of an in vivo analytical method for detecting total anti-UFH activity and pharmacokinetic study in PS and R15 in rats
Establishment of an in vivo analytical method for detecting total anti-UFH activity and pharmacokinetic study in PS and R15 in rats Open
Protamine sulfate (PS), the only U.S. Food and Drug Administration (FDA)-approved heparin antagonist, is encumbered by several drawbacks. R15, a synthetic polyarginine peptide, has proven to be a promising protamine substitute in prior stu…
View article: Characterisation of mAb104 Antibody–Drug Conjugates Targeting a Tumour-Selective HER2 Epitope
Characterisation of mAb104 Antibody–Drug Conjugates Targeting a Tumour-Selective HER2 Epitope Open
Background: The novel anti-HER2 antibody 104 (mAb104) targets a unique tumour-specific epitope, lacks normal tissue binding and can internalise into tumour cells, thus supporting its development into antibody drug conjugates (ADCs). Method…
View article: Figure S5 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S5 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
mAb104 does not affect EGF-independent (left) EGF-dependent (right) downstream signaling in the MAPK and AKT pathways (A, B) SK-BR-3 and (C, D) BT474 cells in-vitro as monotherapy or in combination with trastuzumab or pertuzumab. Cells inc…
View article: Figure S8 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S8 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
The effect of mAb104 treatment on the HER2 and MAPK/mTOR signaling pathway in NCI-N87 tumors after (left) week 1 and (right) week 3 of treatment. Data representative of two independent experiments.
View article: Figure S2 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S2 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
FACS analysis using 10μg/mL antibodies confirming small shift in mAb104 binding in high HER2-expressing (A) NCI-N87, (B) BT-474, (C) SK-BR-3 and (D) NCI-H2170 but not in low HER2-expressing (E) NCI-H838, (F) NCI-H522 and (G) NCI-H1650 cell…
View article: Supplementary Table 1 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Supplementary Table 1 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
Supplementary Table 1
View article: Data from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Data from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
We generated a novel HER2 mAb104, which binds to an epitope in domain II of HER2 that is conformationally exposed in tumors in response to HER2 amplification or activation but is not accessible to antibody binding in normal tissues. Consis…
View article: Supplementary Table 2 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Supplementary Table 2 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
Supplementary Table 2
View article: Figure S4 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S4 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
The effect of mAb104, trastuzumab and pertuzumab monotherapy (left) or in combination (right) on the growth of (A) NCI-N87, (B) BT-474, (C) SK-BR-3 and (D) OE-19 in-vitro as measured by MTS assay. Cells were incubated with antibodies or is…
View article: Figure S3 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S3 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
Immunohistochemical staining with mAb104 and anti-HER2 antibody in (x400) normal (A) brain, (B) large bowel, (C) renal tissue, (D) lung and tumor tissues (E) adenocarcinoma bowel, (F) adenomacarcinoma lung, (G) squamous carcinoma lung, (H)…
View article: Figure S6 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S6 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
mAb104 does not affect EGF-independent (left) EGF-dependent (right) downstream signaling in the MAPK and AKT pathways (A, B) NCI-N87 and (C, D) OE-19 cells in-vitro as monotherapy or in combination with trastuzumab or pertuzumab. Cells inc…
View article: Supplementary Data from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Supplementary Data from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
Supplementary Data
View article: Figure S7 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S7 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
mAb104 binding and anti-tumor effects in gastric OE-19 cancer xenograft (A) Binding of 10μg/mL of Trastuzumab, Pertuzumab and mAb104 (green) to OE-19 cells. B, Mice bearing OE-19 xenografts (n = 5) were treated with Trastuzumab, Pertuzumab…
View article: Figure S1 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2
Figure S1 from Characterization of mAb104, a mAb Targeting a Conformationally Exposed, Tumor-Specific Epitope of HER2 Open
Comparative binding of mAb104, mAb105, mAb106 and mAb107 to the HER2 extracellular domain, circularized and linear peptide immunogens which the antibodies were generated against, or control irrelevant peptide, using an ELISA based assay. S…
View article: Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial
Interferon-α Nasal Spray Prophylaxis Reduces COVID-19 in Cancer Patients: A Randomized, Double-Blinded, Placebo-Controlled Trial Open
Background We evaluated whether a daily nasal spray of interferon-alpha (IFN-α) would reduce the incidence of COVID-19 or community-acquired respiratory viral infections in adult cancer patients. Methods In this multicenter, randomized, do…
View article: Molecular Decoding of Phytohormone Crosstalk: JA-Mediated Key Regulatory Nodes and Signal Integration
Molecular Decoding of Phytohormone Crosstalk: JA-Mediated Key Regulatory Nodes and Signal Integration Open
Jasmonates (JAs) are crucial phytohormones governing plant growth and defense against stresses. This review synthesizes the intricate molecular mechanisms underlying JA crosstalk with key hormones: auxin (AU), gibberellin (GA), abscisic ac…
View article: Genomic Investigation of a Bacillus subtilis Strain Sourced from Commercially Available Milk Powder in China Reveals Potential Risk Factors
Genomic Investigation of a Bacillus subtilis Strain Sourced from Commercially Available Milk Powder in China Reveals Potential Risk Factors Open
This study characterizes Bacillus subtilis LIN78, a genomically plastic strain isolated from Chinese milk powder. It exhibits adaptation to food environments via horizontal gene transfer, stress tolerance, and spoilage traits, while carryi…
View article: Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas
Tumor-initiating genetics and therapy drive divergent molecular evolution in IDH-mutant gliomas Open
Astrocytomas and oligodendrogliomas are slow-growing and treatment-sensitive IDH-mutant gliomas diagnosed at ages 30-50. Local tumor regrowth and treatment resistance is inevitable resulting in 3-10 year astrocytoma and up to >20 years oli…
View article: Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Supplementary Data 1 from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Supplementary material
View article: Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Data from INTERLINK-1: A Phase III, Randomized, Placebo-Controlled Study of Monalizumab plus Cetuximab in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma Open
Purpose:Treatment options for recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HNSCC) after failure of immune checkpoint inhibitor treatment and platinum-based chemotherapy are limited. Preliminary data suggested that mona…
View article: Plasma and Fecal Metabolites Combined with Gut Microbiome Reveal Systemic Metabolic Shifts in 60Co Gamma-Irradiated Rats
Plasma and Fecal Metabolites Combined with Gut Microbiome Reveal Systemic Metabolic Shifts in 60Co Gamma-Irradiated Rats Open
Background: High-dose γ-ray exposure (≥7 Gy) in nuclear emergencies induces life-threatening acute radiation syndrome, characterized by rapid hematopoietic collapse (leukocytes <0.5 × 10⁹/L) and gastrointestinal barrier failure. While clin…
View article: Knowledge, attitudes, and practices of family members of children undergoing chemoradiotherapy regarding oral mucositis
Knowledge, attitudes, and practices of family members of children undergoing chemoradiotherapy regarding oral mucositis Open
Family members of children undergoing chemoradiotherapy have adequate knowledge and positive attitudes about oral mucositis, but this does not always lead to proactive practices. Educational interventions should enhance knowledge and encou…